相关实验视频

Updated: Sep 16, 2025

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

乳腺癌治疗中abemaciclib引起的不良反应的危险因素

Xianghua Quan¹, CaiHong Sun², Bing Han¹

¹Department of Clinical Pharmacy, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China.

Frontiers in oncology

|July 7, 2025

概括

这项研究分析了与abemaciclib治疗的乳腺癌患者的不良反应,abemaciclib是一种依赖于环素的激酶4/6 (CDK4/6) 抑制剂. 年龄,胃肠道疾病和ECOG评分被确定为腹和中性质减退的危险因素.

科学领域:

在瘤学瘤学.
药理学药理学是指药理学的学科.

背景情况:

循环素依赖性激酶4/6 (CDK4/6) 抑制剂改善了激素受体阳性 (HR+) /人体表皮生长因子受体2-阴性 (HER2-) 乳腺癌 (BC) 的存活率.
越来越多地使用CDK4/6抑制剂,需要注意它们的安全性和相关的不良反应.

研究的目的:

在乳腺癌患者中分析与abemaciclib相关的不良反应.
为了确定腹和中性质减肥的危险因素,对abemaciclib.com最常见的不良反应.

主要方法:

对216名接受abemaciclib.lib治疗的乳腺癌患者的回顾性分析.
根据临床管理和共识指南对不良影响的评估.
单变量和多变量逻辑回归分析,以确定影响腹和中性衰竭的因素.

主要成果:

阿贝马西克利布 (Abemaciclib) 显示出可管理的安全性概况,并且耐受性良好.
胃肠道,血液,肝脏,脏,肌肉骨和皮肤系统受到不良事件的影响最大.
2-3级腹的独立风险因素包括年龄和先前存在的胃肠道疾病.
ECOG评分与3-4级中性质衰竭风险有关,而基线BMI,WBC和ALB是保护性的.

结论:

阿贝马西克利布 (Abemaciclib) 是乳腺癌的一般安全和耐受性良好的治疗选择.
识别腹和中性质减肥的危险因素有助于合理的临床应用和患者管理.
进一步的研究可以通过减轻已识别的不良反应来优化abemaciclib的使用.

关键词:

在CDK4/6基因酶中,一个有着巨大的力量.乳腺癌乳腺癌乳腺癌腹腹腹腹腹腹腹中性变质症中性变质症中性变质症

更多相关视频

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

Published on: May 27, 2021

High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds

High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds

Published on: August 18, 2023

相关概念视频

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Factors Affecting Protein-Drug Binding: Patient-Related Factors

Factors Affecting Protein-Drug Binding: Patient-Related Factors

Protein-drug binding, a pivotal aspect of pharmacokinetics, is subject to considerable variability influenced by an array of patient-related factors. The intricate interplay of age, individual differences, and pathological conditions significantly impact the binding dynamics and subsequent pharmacological effects.
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...

Factors Influencing Drug Absorption: Disease States and Pharmacology

Factors Influencing Drug Absorption: Disease States and Pharmacology

Multiple disease states can significantly influence the oral drug absorption process by affecting blood flow and the functionality of the gastrointestinal (GI) system. Various GI diseases, including conditions that alter GI motility, such as diarrhea, decreased acid secretions (achlorhydria), and infections, have been associated with reduced drug absorption.
Substances such as alcohol and specific drugs, including antineoplastics, can also negatively impact drug absorption. For instance,...

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...